This company has been acquired
AKUS Stock Overview
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Akouos, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.29 |
| 52 Week High | US$13.60 |
| 52 Week Low | US$2.32 |
| Beta | -0.56 |
| 1 Month Change | 1.22% |
| 3 Month Change | 270.20% |
| 1 Year Change | 50.34% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -39.59% |
Recent News & Updates
Recent updates
Is Akouos (NASDAQ:AKUS) In A Good Position To Deliver On Growth Plans?
Sep 19
Akouos stock rises 11% on FDA nod to start gene therapy trial for hearing loss
Sep 13We Think Akouos (NASDAQ:AKUS) Needs To Drive Business Growth Carefully
Jun 04We Think Akouos (NASDAQ:AKUS) Can Afford To Drive Business Growth
Feb 19Companies Like Akouos (NASDAQ:AKUS) Are In A Position To Invest In Growth
Oct 28Here's Why We're Not Too Worried About Akouos' (NASDAQ:AKUS) Cash Burn Situation
Jun 26We Think Akouos (NASDAQ:AKUS) Can Afford To Drive Business Growth
Mar 04Did Akouos, Inc. (NASDAQ:AKUS) Insiders Buy Up More Shares?
Jan 10Akouos (NASDAQ:AKUS) Is In A Good Position To Deliver On Growth Plans
Nov 18Shareholder Returns
| AKUS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.9% | 5.0% | 0.5% |
| 1Y | 50.3% | -11.6% | 11.1% |
Return vs Industry: AKUS exceeded the US Biotechs industry which returned -10.3% over the past year.
Return vs Market: AKUS exceeded the US Market which returned -16.1% over the past year.
Price Volatility
| AKUS volatility | |
|---|---|
| AKUS Average Weekly Movement | 27.9% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: AKUS's share price has been volatile over the past 3 months.
Volatility Over Time: AKUS's weekly volatility has increased from 20% to 28% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 103 | Manny Simons | www.akouos.com |
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company’s precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene.
Akouos, Inc. Fundamentals Summary
| AKUS fundamental statistics | |
|---|---|
| Market cap | US$491.02m |
| Earnings (TTM) | -US$92.59m |
| Revenue (TTM) | n/a |
Is AKUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKUS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$92.59m |
| Earnings | -US$92.59m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.51 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AKUS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/12/01 16:55 |
| End of Day Share Price | 2022/11/30 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Akouos, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| null null | BTIG |
| Joseph Pantginis | H.C. Wainwright & Co. |